Alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency | |
---|---|
Other names | α1-antitrypsin deficiency |
intravenous infusions of A1AT protein[2] | |
Prognosis | Life expectancy ~50 years (smokers), nearly normal (non-smokers)[3] |
Frequency | 1 in 2,500 (Europeans)[1] |
Alpha-1 antitrypsin deficiency (A1AD or AATD) is a
A1AD is due to a mutation in the
Treatment of lung disease may include
The condition affects about 1 in 2,500 people of European descent.
Signs and symptoms
Individuals with A1AD may develop
A1AD may cause several manifestations associated with liver disease, which include impaired liver function and cirrhosis. In newborns, alpha-1 antitrypsin deficiency can result in early onset jaundice followed by prolonged jaundice. Between 3% and 5% of children with ZZ mutations develop life-threatening liver disease, including liver failure.[9] A1AD is a leading reason for liver transplantation in newborns.[9] In newborns and children, A1AD may cause jaundice, poor feeding, poor weight gain, hepatomegaly and splenomegaly.[9]
Apart from COPD and chronic liver disease, α1-antitrypsin deficiency has been associated with necrotizing panniculitis (a skin condition) and with granulomatosis with polyangiitis in which inflammation of the blood vessels may affect a number of organs but predominantly the lungs and the kidneys.[10]
Genetics
Serpin peptidase inhibitor, clade A, member 1 (SERPINA1) is the gene that encodes the protein alpha-1 antitrypsin. SERPINA1 has been localized to chromosome 14q32. Over 75 mutations of the SERPINA1 gene have been identified, many with clinically significant effects.[11] The most common cause of severe deficiency, PiZ, is a single base-pair substitution leading to a glutamic acid to lysine mutation at position 342 (dbSNP: rs28929474), while PiS is caused by a glutamic acid to valine mutation at position 264 (dbSNP: rs17580). Other rarer forms have been described [citation needed].
Pathophysiology
A1AT is a glycoprotein mainly produced in the
Normal blood levels of alpha-1 antitrypsin may vary with analytical method but are typically around 1.0-2.7 g/L.
With A1AT deficiency, the pathogenesis of the lung disease is different from that of the liver disease, which is caused by the accumulation of abnormal A1AT proteins in the liver, resulting in liver damage.
Diagnosis
The gold standard of diagnosis for A1AD consists of blood tests to determine the phenotype of the AAT protein or genotype analysis of DNA.[9] Liver biopsy is the gold standard for determining the extent of hepatic fibrosis and assessing for the presence of cirrhosis.[9]
A1AT deficiency remains undiagnosed in many patients. Patients are usually labeled as having COPD without an underlying cause. It is estimated that about 1% of all COPD patients actually have an A1AT deficiency. Testing is recommended in those with COPD, unexplained liver disease, unexplained bronchiectasis, granulomatosis with polyangiitis or necrotizing panniculitis.[10] American guidelines recommend that all people with COPD are tested,[10] whereas British guidelines recommend this only in people who develop COPD at a young age with a limited smoking history or with a family history.[19] The initial test performed is serum A1AT level. A low level of A1AT confirms the diagnosis and further assessment with A1AT protein phenotyping and A1AT genotyping should be carried out subsequently.[11]
As
Other detection methods include use of
- PiMM: 100% (normal)
- PiMS: 80% of normal serum level of A1AT
- PiSS: 60% of normal serum level of A1AT
- PiMZ: 60% of normal serum level of A1AT
- PiSZ: 40% of normal serum level of A1AT
- PiZZ: 10–15% (severe alpha-1 antitrypsin deficiency)
Treatment
Treatment of lung disease may include
People with lung disease due to A1AD may receive intravenous infusions of alpha-1 antitrypsin, derived from donated human plasma. This augmentation therapy is thought to arrest the course of the disease and halt any further damage to the lungs. Long-term studies of the effectiveness of A1AT replacement therapy are not available.[20] It is currently recommended that patients begin augmentation therapy only after the onset of emphysema symptoms.[11] As of 2015 there were four IV augmentation therapy manufacturers in the United States, Canada, and several European countries. IV therapies are the standard mode of augmentation therapy delivery.[citation needed]
Liver disease due to A1AD does not include any specific treatment, beyond routine care for chronic liver disease.
Epidemiology
People of Northern
Another study detected a frequency of 1 in 1550 individuals.[21] The highest prevalence of the PiZZ variant was recorded in the northern and western European countries with mean gene frequency of 0.0140.[21] Worldwide, an estimated 1.1 million people have A1AT deficiency and roughly 116 million are carriers of mutations.[21]
A1AD is one of the most common genetic diseases worldwide and the second most common metabolic disease affecting the liver.[22]
History
A1AD was discovered in 1963 by
The link with liver disease was made six years later, when Harvey Sharp et al. described A1AD in the context of liver disease.[24]
Research
Recombinant and inhaled forms of A1AT treatment are being studied.[25]
References
- ^ a b c d e f g h i j k l m n o p q "alpha-1 antitrypsin deficiency". Genetics Home Reference. January 2013. Retrieved 12 December 2017.
- ^ a b c d e f g h i j k l m n "Alpha-1 antitrypsin deficiency". GARD. 2016. Retrieved 12 December 2017.
- ^ ISBN 9780199556373.
- PMID 28364818.
- ^ PMID 22536580.)
{{cite journal}}
: CS1 maint: numeric names: authors list (link - ISBN 9781848151154.
- ^ ISBN 978-0-7216-0187-8.
- ^ Vestbo J (2013). "Diagnosis and Assessment" (PDF). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 9–17. Archived from the original (PDF) on 28 March 2016. Retrieved 9 August 2019.
- ^ S2CID 52883809.
- ^ PMID 28848891.
- ^ PMID 19553648.
- PMID 3260605.
- S2CID 53017522.
- ISBN 9780123740014.
- PMID 21147616.
- ^ "Emphysema". Mayo Clinic. Mayo Foundation for Medical Education and Research (MFMER). Retrieved 16 November 2021.
- PMID 22912357. Retrieved 17 January 2014.
- PMID 29446109.
- ^ "Chronic obstructive pulmonary disease in over 16s: diagnosis and management". www.nice.org.uk. National Institute for Health and Care Excellence. December 2018. Retrieved 11 August 2019.
- PMID 27644166.
- ^ PMID 14760160.
- ISBN 978-0323609623.
- .
- PMID 4182334.
- PMID 38112023.